Presentation Overview
Learn how to leverage integrated digital cognitive assessments and patient reports to achieve advanced insights, streamlined delivery and lower burden.
Watch the webinar to learn:
- The value of assessing cognitive safety and tolerability throughout the drug development process
- Addressing current regulatory guidance
- How data from objective performance-based assessments can be integrated with other sources of information to inform trial decision-making
- Key considerations for selecting and optimizing computerized cognitive assessments
- Lessons learned from global cognitive safety studies across oncology, cardiovascular, migraine, epilepsy
Speakers
- Chris Edgar, Senior Vice President, Clinical Science, Cogstate
- Ken Faulkner, Vice President, eCOA Scientific Services, ERT
